The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Cruz announces that investors with losses related to Regeneron Pharmaceuticals ... distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

IF YOU SUFFERED A LOSS ON YOUR REGENERON INVESTMENTS ... distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. To further protect the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...

Learn more about whether AbbVie Inc. or Regeneron Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Regeneron's solid financials, including nearly $18bn in cash and minimal debt, make REGN stock a compelling buy despite recent share price declines. Q4 revenues were up 10% year-on-year ...

While Regeneron doesn’t make vaccines specifically, its monoclonal antibody therapy provides a "passive vaccine" effect, temporarily protecting against infections. Dupixent Could Gain 30% More U ...

The company's robust performance makes it increasingly likely that the stock price has found a bottom in the past several weeks following months of a relentless bearish trend. As such, Regeneron ...